<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Achondroplasia</z:e> is the most common form of human <z:hpo ids='HP_0003510'>dwarfism</z:hpo> caused by a mutation in the fibroblast growth factor receptor 3 (FGFR3), resulting in abnormal endochondral bone formation </plain></SENT>
<SENT sid="1" pm="."><plain>C-type natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> (CNP) is a potent stimulator of endochondral bone growth and represents a potential therapy for <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We have developed a novel, simple and cost effective method to produce a CNP analogue, PG-CNP37, at a large scale from Escherichia coli </plain></SENT>
<SENT sid="3" pm="."><plain>A PG-CNP37 fusion protein was over-expressed as inclusion bodies in E. coli, which were purified then cleaved by <z:chebi fb="3" ids="30751">formic acid</z:chebi> to release the PG-CNP37 <z:chebi fb="7" ids="16670">peptide</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Approximately 0.5g of 95% pure, soluble and active PG-CNP37 <z:chebi fb="7" ids="16670">peptide</z:chebi> was produced from 1L of culture using this method and may represent a viable means for large-scale production of other therapeutic <z:chebi fb="7" ids="16670">peptides</z:chebi> </plain></SENT>
</text></document>